Financial Performance - The company's revenue for Q1 2021 was ¥278,106,139.44, representing a 73.31% increase compared to ¥160,465,601.52 in the same period last year[9]. - Net profit attributable to shareholders reached ¥46,447,471.21, a significant increase of 553.18% from ¥7,110,935.41 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥37,008,478.80, up 602.59% from ¥5,267,419.58 year-on-year[9]. - Basic earnings per share increased to ¥0.20, reflecting a growth of 566.67% compared to ¥0.03 in the same period last year[9]. - Total operating revenue for Q1 2021 reached ¥278,106,139.44, a significant increase from ¥160,465,601.52 in the same period last year, representing a growth of approximately 73.4%[74]. - The company's total profit for the current period was ¥54,462,950.90, compared to ¥7,274,839.99 in the previous period, an increase of 648.0%[80]. - The company reported other income of ¥10,235,579.41, significantly higher than ¥2,369,352.20 in the previous period, an increase of 331.5%[80]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,214,152,832.99, a 7.38% increase from ¥1,130,719,874.02 at the end of the previous year[9]. - The company's total assets as of March 31, 2021, amounted to ¥1,068,924,382.18, compared to ¥1,010,169,893.59 at the end of 2020, indicating an increase of about 5.8%[72]. - The total liabilities increased to ¥144,601,964.50 from ¥138,278,904.69, reflecting a rise of approximately 4.7%[72]. - The equity attributable to shareholders of the parent company rose to ¥924,322,417.68, up from ¥871,890,988.90, marking an increase of around 6.0%[72]. - The company's cash and cash equivalents increased to CNY 145.12 million from CNY 135.26 million, reflecting improved liquidity[56]. - Cash and cash equivalents at the end of the period reached 138,466,537.36, compared to 115,159,925.13 at the end of the previous period, marking an increase of approximately 20.2%[98]. Cash Flow - The net cash flow from operating activities was ¥13,000,922.98, a decrease of 15.81% from ¥15,442,989.83 in the same period last year[9]. - Cash inflow from operating activities totaled 298,414,653.06, compared to 184,542,238.28 in the previous period, reflecting a growth of approximately 61.6%[96]. - Cash received from sales of goods and services was 278,435,959.74, up from 177,197,979.34, indicating a year-over-year increase of about 57.1%[92]. - Cash inflow from financing activities was 20,000,000.00, up from 9,500,000.00, representing a growth of 110.5%[98]. - Cash outflow from financing activities decreased to 2,697,620.21 from 17,600,155.73, showing a reduction of about 84.7%[98]. Research and Development - Research and development expenses increased by 59.49% to CNY 23.85 million, reflecting higher spending on R&D projects[23]. - The company has several ongoing R&D projects, including indomethacin gel and hydrochloride acotiamide tablets, currently in clinical research stages[27]. - JiuDian Pharmaceutical has multiple R&D projects in progress, including 10 projects focused on anti-inflammatory and analgesic drugs, with all in the preclinical research stage[19]. - The company has a total of 17 drug development projects in the pre-registration research phase, focusing on various therapeutic areas including anti-inflammatory and analgesic drugs[34]. - The company emphasizes the importance of product and technology development as a core competitive advantage, with a focus on risk control in the R&D process[38]. Market Strategy and Compliance - The company is committed to enhancing its market presence through the development of innovative products and potential market expansions[32]. - The implementation of the "Two Invoice System" has led to an increase in the proportion of sales through cooperative distribution models, enhancing market reach[44]. - Environmental compliance remains a focus, with the company implementing a high-standard EHS management system to mitigate potential regulatory risks[46]. - The company is addressing potential risks related to intellectual property protection and market competition through systematic management and legal compliance[39]. - The company is diversifying its product line to mitigate the impact of antibiotic regulation on revenue growth[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,633[12]. - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[68].

Financial Performance - The company reported a total revenue of 234,680,000, with a cash dividend of 0.43 per 10 shares (including tax) to all shareholders[14]. - In 2020, the company's operating income reached CNY 978,159,132, representing a 5.85% increase compared to CNY 924,061,198 in 2019[36]. - The net profit attributable to shareholders was CNY 82,259,768, a significant increase of 49.38% from CNY 55,065,854 in the previous year[36]. - The net profit after deducting non-recurring gains and losses was CNY 67,246,404, up 44.94% from CNY 46,394,577 in 2019[36]. - The net cash flow from operating activities increased by 65.30% to CNY 149,994,592 from CNY 90,740,744 in 2019[36]. - Basic and diluted earnings per share rose to CNY 0.35, a 52.17% increase from CNY 0.23 in 2019[36]. - Total assets at the end of 2020 were CNY 1,130,719,874, reflecting a 5.47% increase from CNY 1,072,099,019 in 2019[36]. - The net assets attributable to shareholders increased by 9.69% to CNY 835,682,214 from CNY 761,870,926 in 2019[36]. - The weighted average return on equity was 10.31%, up from 7.45% in the previous year[36]. - The company achieved a revenue of 978.16 million yuan, representing a year-on-year growth of 5.85%[58]. - The net profit attributable to shareholders reached 82.26 million yuan, marking a significant increase of 49.38% compared to the previous year[58]. - The company reported a total of 5.96% growth in main business revenue compared to the previous year[145]. - The company's main business revenue reached ¥975,709,020.77, representing a year-on-year increase of 5.96%[148]. - The revenue from pharmaceutical preparations was ¥794,774,519.70, with a growth of 21.29% compared to the previous year[148]. - The overall gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[139]. Research and Development - The company emphasizes the importance of product and technology development as a core competitive advantage, although it faces risks related to market trends and funding[6]. - The company has a strong focus on the consistency evaluation of generic drugs to ensure quality and efficacy[26]. - The company employs a research and development model primarily based on independent innovation, supplemented by collaborative development and technology introduction[57]. - The company has established stable partnerships with numerous research institutions to enhance its technological innovation capabilities[57]. - The company has a strong emphasis on research and development, with multiple projects in the pipeline aimed at addressing unmet medical needs[19][20][21][22][23][24][25][26][27][28][29]. - The company is committed to enhancing its research and development capabilities to innovate and bring new therapies to market[134]. - The company plans to continue to invest in R&D, focusing on the development of modified and innovative drugs, while increasing its R&D expenditure[184]. - The company has multiple ongoing R&D projects, with several products having obtained production approval, including Loxoprofen Sodium Tablets and Irbesartan Tablets[120]. - The company has a total of 384 R&D personnel, representing 30.16% of the workforce, with R&D investment accounting for 8.35% of total revenue[163]. Market Strategy and Competition - The company is facing increased competition in the pharmaceutical market due to ongoing reforms in the medical insurance system and drug procurement policies[9]. - Future strategies include expanding market presence and enhancing R&D capabilities for new products and technologies[26]. - The company is adapting its sales model to increase the proportion of cooperative distribution, which has been positively affected by the implementation of the "two-invoice system"[10]. - The company is focused on completing the consistency evaluation of its generic drugs, which is crucial for maintaining market competitiveness[9]. - The company is actively pursuing opportunities for market expansion and potential acquisitions to strengthen its competitive position[105]. - The company aims to leverage its core patented products to drive future revenue growth, particularly in the therapeutic areas of chronic gastritis and hypertension[134]. - The company is exploring mergers and acquisitions to enhance its product portfolio and market reach[134]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 300 million yuan allocated for potential deals[139]. Regulatory and Compliance - The company has passed various international certifications and audits, allowing its products to be sold in multiple countries and regions, including India and Europe[65]. - The company is committed to quality-centered production processes and compliance-driven organizational improvements[120]. - The company has registered a total of 148 domestic trademarks, with 37 new trademarks added during the reporting period[87]. - The company has fulfilled its commitments regarding shareholding restrictions and has been compliant with the lock-up period since its IPO in 2017[199]. - The company’s major shareholders have committed to not transferring their shares for a period of 36 months post-IPO, ensuring stability in shareholding[199]. - The company is currently in the process of fulfilling its commitments regarding the transfer of shares by its directors and senior management, with a limit of 25% per year[199]. Environmental and Operational Risks - The company acknowledges the environmental risks associated with its production processes and the potential for increased operational costs due to stricter environmental regulations[14]. - The company has implemented measures to strengthen accounts receivable management to mitigate the risk of bad debts as its business scales up[12]. - The company aims to strengthen supplier management and cost awareness to ensure production safety and environmental protection[185]. Product Development and Offerings - Key products include Loxoprofen Sodium Gel, Pantoprazole Sodium Enteric-coated Tablets, and Metronidazole, targeting various medical conditions such as osteoarthritis and digestive ulcers[52]. - The company is committed to expanding its product offerings in the OTC pharmaceutical market, with several projects under development[42][44]. - The company has developed and produced 54 pharmaceutical excipients, showcasing its competitive advantage in the market[75]. - The company is focused on enhancing its market presence through the introduction of new products and technologies[19][20][21][22][23][24][25][26][27][28][29]. - The company is actively working on consistency evaluation for several drugs, including Pantoprazole Sodium Enteric-Coated Tablets and Levocetirizine Hydrochloride Capsules, both of which have passed the evaluation[127].

Financial Performance - Net profit attributable to shareholders of the listed company reached ¥22,364,024.43, an increase of 139.54% year-on-year[9]. - Operating income for the reporting period was ¥263,531,787.85, reflecting a growth of 12.94% compared to the same period last year[9]. - Basic earnings per share were ¥0.10, representing a 150.00% increase compared to the same period last year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,841,146.66, an increase of 98.19% year-on-year[9]. - The company reported a net profit increase, with retained earnings rising from CNY 213,817,633.47 to CNY 260,555,179.97, an increase of approximately 22%[42]. - The net profit for the current period is CNY 25,657,091.12, compared to CNY 14,068,283.43 in the previous period, indicating a significant increase of approximately 82.5%[62]. - The total comprehensive income attributable to the parent company's owners is CNY 22,364,024.43, significantly higher than CNY 9,336,294.52 in the previous period, indicating an increase of approximately 139.5%[61]. - The company reported a total comprehensive income of CNY 51,875,888.05, an increase from CNY 48,051,606.23, indicating a growth of about 5.9%[79]. Cash Flow - The net cash flow from operating activities was ¥45,833,072.05, a significant increase of 617.56% year-on-year[9]. - Net cash flow from operating activities surged by 2,355.87% to ¥96,365,368.27 from ¥3,923,876.69, attributed to increased government subsidies received and reduced payments for goods[20]. - Cash inflow from operating activities totaled CNY 725,617,335.80, compared to CNY 674,753,601.34 in the previous period, indicating an increase of about 7.5%[82]. - The net cash flow from operating activities was CNY 96,365,368.27, significantly higher than CNY 3,923,876.69 in the previous period, showing a substantial improvement[82]. - Cash inflow from financing activities was CNY 9,500,000.00, a decrease from CNY 85,000,000.00 in the previous period, indicating a decline of approximately 88.8%[85]. - The net cash flow from financing activities was -CNY 72,651,373.62, compared to CNY 33,065,978.46 in the previous period, reflecting a negative shift[85]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,055,530,066.32, a decrease of 1.55% compared to the end of the previous year[9]. - Current liabilities decreased significantly from CNY 200,543,702.32 to CNY 130,068,196.04, a reduction of about 35%[39]. - Non-current liabilities increased from CNY 109,684,391.04 to CNY 116,853,397.66, representing a rise of approximately 6.5%[39]. - The total equity attributable to shareholders rose from CNY 761,870,926.12 to CNY 808,608,472.62, an increase of about 6.1%[42]. - The company's total liabilities decreased from CNY 310,228,093.36 to CNY 246,921,593.70, a reduction of approximately 20.4%[39]. - Total liabilities reached $150.52 million, with current liabilities at $145.55 million and non-current liabilities at $4.97 million[107]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,617[13]. - The largest shareholder, Zhu Zhihong, held 37.16% of the shares, totaling 87,210,000 shares[13]. Operational Costs and Expenses - The total operating costs for the current period are CNY 243,128,400.83, compared to CNY 217,018,501.83 in the previous period, which is an increase of approximately 12.1%[52]. - The company's sales expenses have risen to CNY 138,020,268.69 from CNY 102,851,251.44, marking an increase of approximately 34.0%[59]. - Research and development expenses for the current period amount to CNY 19,254,954.20, down from CNY 24,115,268.35 in the previous period, reflecting a decrease of about 20.2%[59]. - Financial expenses increased by 46.88% to ¥3,757,618.18 from ¥2,558,368.14 due to higher borrowing interest[20]. Future Plans - The company plans to issue convertible bonds to unspecified objects, with the proposal approved by the board and shareholders[23][24]. - The company plans to continue focusing on market expansion and new product development strategies in the upcoming quarters[66]. Compliance and Standards - The company has no violations regarding external guarantees or non-operating fund occupation during the reporting period[25][26]. - The company has implemented new revenue and leasing standards starting from 2020, affecting financial reporting[92].

证券代码：300705 证券简称：九典制药 公告编号：2020-042 湖南九典制药股份有限公司 关于参加湖南辖区上市公司 2020 年度 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,使广大投资者能更深入全面了解公司情 况，湖南九典制药股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合举办 的"湖南辖区上市公司 2020 年度投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台采取网络远程的方式举行，投资者可以登录"全景·路演天下"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动，活动时间为 2020 年 9 月 11 日（星期五）15:00-17:00。 届时公司副总经理、董事会秘书李敏先生和证券事务代表曾蕾女士将通过网 络在线问答互动的形式，与投资者进行沟通和交流。 欢迎广大投资者积极参与！ 特此公告。 湖南九典 ...

Financial Performance - The company reported a total revenue of 150 million yuan for the first half of 2020, representing a year-on-year increase of 20%[19] - The net profit attributable to shareholders was 30 million yuan, up 15% compared to the same period last year[19] - Operating revenue for the reporting period was ¥393,292,464.63, a decrease of 7.71% compared to the same period last year[27] - Net profit attributable to shareholders was ¥32,822,002.07, an increase of 15.08% year-over-year[27] - The gross margin for the first half of 2020 was reported at 45%, slightly down from 48% in the previous year[19] - Future guidance indicates an expected revenue growth of 15-20% for the second half of 2020, driven by new product launches and market expansion efforts[19] - The pharmaceutical formulation segment generated revenue of 308.26 million yuan, a year-on-year increase of 7.44%[86] - The raw materials segment reported revenue of 40.02 million yuan, up 33.29% compared to the previous year[86] - The excipients segment saw a significant decline in revenue to 28.23 million yuan, down 68.09% year-on-year, due to a strategic shift away from low-margin products[86] Research and Development - The company plans to invest 50 million yuan in R&D for new drug development in the upcoming year[19] - The company is focusing on the development of generic drugs, with a target of launching five new products by the end of 2021[19] - The company's R&D investment accounted for 8.80% of sales revenue, demonstrating a strong commitment to product development and technological reserves[52] - The company has ongoing patent applications for new products, including Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets[101] - The company is transitioning from generic drugs to improved new drugs and innovative drugs, focusing on high-difficulty generics[87] - The company has 30 ongoing research projects, with several products already submitted for production approval, including Ketoprofen Patch and Losartan Tablets[93] Market Expansion and Customer Base - User data indicates a 25% increase in the number of active customers, reaching 200,000 by the end of June 2020[19] - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 30%[19] - The company has established long-term cooperative relationships with domestic and international clients, exporting raw materials to over 30 countries and regions[59] - The company is actively promoting its corporate culture and core values among employees[89] Compliance and Regulatory Environment - The company is committed to maintaining compliance with the latest drug management laws and regulations, which have impacted the issuance of GMP and GSP certifications[70] - The company has taken measures to ensure compliance with regulatory requirements for drug production licenses to avoid operational disruptions[126] - The company has not faced any major litigation or regulatory penalties during the reporting period, reflecting a stable legal standing[10][146] Environmental Responsibility - The company has implemented measures to meet environmental standards, with specific pollutants being monitored[168] - The total discharge of chemical oxygen demand (COD) was reported at 2.57 tons per year, with ammonia nitrogen at 0.38 tons per year[170] - The company has established an emergency response plan for environmental incidents, with drills conducted regularly[180] - The company has a solid waste management system in place, with hazardous waste being disposed of through qualified companies after reaching a certain volume[178] Shareholder Information - No cash dividends will be distributed to shareholders for this period, as the company aims to reinvest profits into growth initiatives[7] - The largest shareholder, Zhu Zhihong, holds 87,210,000 shares, representing 37.16% of the total shares[198] - The total number of common stock shareholders at the end of the reporting period was 15,530[198] - The company has a total of 135,620,760 restricted shares held by shareholders, with 332,182 shares released from restriction during the period[197] Financial Management - The company has implemented strict budget controls and conducted various internal audits to strengthen financial management[89] - The company has established a tracking mechanism for accounts receivable and enhanced credit management to reduce the risk of bad debts[8][131] - The company has not engaged in any significant equity or non-equity investments during the reporting period[113] - The company has outstanding long-term borrowings (including those due within one year) amounting to 57.6 million yuan[120]

Financial Performance - Total revenue for Q1 2020 was ¥160,465,601.52, a decrease of 10.07% compared to ¥178,432,234.08 in the same period last year[9] - Net profit attributable to shareholders was ¥7,110,935.41, down 31.73% from ¥10,416,498.69 year-on-year[9] - Net profit excluding non-recurring gains and losses was ¥5,267,419.58, a decline of 41.30% from ¥8,972,799.71 in the previous year[9] - Basic earnings per share decreased to ¥0.03, down 25.00% from ¥0.04 in the previous year[9] - The company reported a net profit of CNY 220,928,568.89 as of March 31, 2020, compared to CNY 213,817,633.47 for the same period in 2019, reflecting a growth of approximately 3.2%[62] - The net profit for the current period is 5,747,917.21, a decrease from 17,852,509.29 in the previous period, representing a decline of approximately 68.3%[88] - Operating profit for the current period is 5,875,071.36, down from 20,153,026.59, indicating a decrease of about 70.9%[88] - Total operating revenue for the current period is CNY 160,465,601.52, a decrease of 10.06% from CNY 178,432,234.08 in the previous period[71] Cash Flow - Operating cash flow improved significantly, with a net cash flow from operating activities of ¥15,442,989.83, compared to a negative cash flow of ¥20,630,363.28 in the same period last year, representing a 174.86% increase[9] - Cash flow from operating activities generated a net amount of 15,442,989.83, compared to a net outflow of -20,630,363.28 in the previous period[92] - Cash inflow from operating activities totaled 184,542,238.28, slightly down from 188,936,750.23 in the previous period[89] - Cash outflow from operating activities was 169,099,248.45, compared to 209,567,113.51 in the previous period, showing a decrease of about 19.3%[92] - The company incurred a cash outflow of 17,515,013.80 for investing activities, compared to 57,326,964.15 in the previous period, indicating a reduction of approximately 69.5%[92] - The company received cash from financing activities totaling 9,500,000.00, while cash outflow for financing activities was 17,600,155.73, resulting in a net cash flow of -8,100,155.73[95] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,051,864,193.51, a decrease of 1.89% from ¥1,072,099,019.48 at the end of the previous year[9] - Current assets decreased to CNY 441,422,213.05 as of March 31, 2020, down from CNY 454,178,464.84 as of December 31, 2019, representing a decline of approximately 2.7%[53] - Total liabilities decreased to CNY 282,882,331.97 from CNY 310,228,093.36, a reduction of about 8.8%[59] - Total equity increased to CNY 768,981,861.54 from CNY 761,870,926.12, an increase of about 0.3%[62] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,950[12] - Major shareholder Zhu Zhihong holds 37.16% of the shares, totaling 87,210,000 shares[12] Product Development and Market Strategy - The company has several new products in the pipeline, including Ketoprofen plaster and Loxoprofen sodium tablets, with production application reports submitted[25] - The company plans to continue expanding its market presence and launching new products in the upcoming quarters[25] - The company is actively developing new products with market potential and higher profit margins to mitigate the impact of price adjustments on profitability[34] - The company has ongoing research projects for 16 new drug formulations, including treatments for hypertension and Parkinson's disease, with various stages of development[29] - The company has submitted applications for production batches for several raw material drugs, including those for dyslipidemia and anti-thrombotic drugs[29] Challenges and Risks - The company reported a significant impact on sales and logistics due to the COVID-19 pandemic, affecting normal operations[33] - The company is at risk of product or technology development failures due to uncertainties in market trends and funding[40] - A portion of the company's main products is included in national and provincial medical insurance lists, and any exclusion from these lists could adversely affect operations[39] - The company faces high costs associated with the consistency evaluation of its generic drugs, which could affect market competitiveness if not completed on time[38] Quality and Compliance - The company has established a strict quality management system to ensure compliance with national standards throughout the production process[39] - The company is committed to maintaining its production licenses and certifications to ensure uninterrupted operations[44] Research and Development - Research and development expenses for the current period are CNY 14,954,203.00, slightly up from CNY 14,869,722.43 in the previous period[74] - The company is increasing R&D investment and talent acquisition to maintain competitive advantages and explore new market areas[40] Supplier and Customer Dynamics - The company reported that the top five suppliers accounted for 36.75% of the total annual procurement, down from 42.56% in the same period last year, with no adverse impact on operations[32] - The top five customers contributed 23.77% of the total sales during the reporting period, an increase from 17.78% in the previous year, with no negative effects on the company's operations[33]

Financial Performance - The company's operating revenue for 2019 was CNY 924,061,197.65, representing a 15.31% increase compared to CNY 801,375,318.24 in 2018[31]. - The net profit attributable to shareholders for 2019 was CNY 55,065,853.69, a decrease of 23.50% from CNY 71,985,020.51 in 2018[31]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,394,576.77, down 31.16% from CNY 67,398,623.85 in 2018[31]. - The net cash flow from operating activities increased by 32.99% to CNY 90,740,744.38 in 2019, compared to CNY 68,233,504.01 in 2018[31]. - The total assets at the end of 2019 were CNY 1,072,099,019.48, reflecting a 13.66% increase from CNY 943,211,123.69 at the end of 2018[31]. - The net assets attributable to shareholders at the end of 2019 were CNY 761,870,926.12, a 6.09% increase from CNY 718,159,433.78 at the end of 2018[31]. - The basic earnings per share for 2019 were CNY 0.23, down 25.81% from CNY 0.31 in 2018[31]. - The diluted earnings per share for 2019 were also CNY 0.23, reflecting the same decrease of 25.81% from CNY 0.31 in 2018[31]. - The weighted average return on equity for 2019 was 7.45%, down from 10.46% in 2018, a decrease of 3.01%[31]. - The company reported quarterly revenues of CNY 264,586,959.05 in Q4 2019, with a net profit of CNY 17,208,870.36 attributable to shareholders[32]. - The company achieved operating revenue of 924.06 million yuan, a year-on-year increase of 15.31%, driven by market expansion and the introduction of new products[47]. - Net profit attributable to shareholders was 55.07 million yuan, a decrease of 23.50% compared to the previous year, primarily due to increased market promotion expenses and higher R&D investments[47]. - The company reported a total revenue of 35,302,380 in the latest quarter, reflecting a growth of 5% compared to the previous quarter[73]. - The company has set a performance guidance of achieving a net profit margin of 20% for the next quarter, up from 18% in the current quarter[73]. - The company reported a revenue of 1.2 billion CNY for the fiscal year 2019, representing a year-over-year growth of 15%[116]. - The net profit for the year was 200 million CNY, an increase of 10% compared to the previous year[116]. - The company aims to set a revenue guidance of 1.5 billion CNY for the next fiscal year, indicating a growth target of 25%[116]. Research and Development - The company has established a comprehensive new drug R&D system, but faces risks related to policy changes and funding shortages[9]. - R&D investment accounted for 11.88% of operating revenue, reflecting the company's commitment to innovation and product development[57]. - The company has established strong partnerships with research institutions to enhance its R&D capabilities and innovation[56]. - The company obtained 88 intellectual property rights during the reporting period, including 1 invention patent, and has a rich reserve of R&D projects across various stages[58]. - The company is actively developing 16 new chemical raw materials, with several projects already submitted for production approval[109]. - The company has paused the research on "Antihypertensive Drugs," indicating a strategic shift in its R&D focus[109]. - The company is conducting research on new formulations such as "Gastroesophageal Reflux Disease" treatments, which are in the small-scale research phase[109]. - The company has submitted supplementary applications for multiple products, including "Pantoprazole Sodium Enteric-coated Tablets," reflecting ongoing product enhancement efforts[110]. - The company is focusing on expanding its product line with new formulations aimed at treating chronic conditions like "Chronic Gastritis" and "Parkinson's Disease"[109]. - The company has a patent application pending for "Pantoprazole Sodium Enteric-coated Tablets," which may enhance its competitive position in the market[110]. - Research and development expenses increased by 20%, totaling 150 million CNY, to support new product development[116]. - The company’s R&D investment in 2019 amounted to ¥109,800,156.23, representing 11.88% of its operating revenue, an increase from 7.17% in 2018[140]. - The number of R&D personnel increased to 353 in 2019, accounting for 31.43% of the total workforce, up from 30.86% in 2018[140]. Market and Competitive Landscape - The pharmaceutical market is experiencing a slowdown in growth, and the company must maintain advantages in product structure and R&D to compete effectively[8]. - The global pharmaceutical market is projected to grow from $989 billion in 2013 to between $1,505 billion and $1,535 billion by 2023, with a compound annual growth rate (CAGR) of 3%-6%[48]. - The domestic pharmaceutical market is expected to maintain high growth, supported by increasing healthcare spending and an aging population[50]. - The company has a complete industrial chain from raw materials to drug formulations, with leading synthesis technology for key products[52]. - The company’s core competitive advantages remain intact, with no significant disruptions reported in management or technology[56]. - The company is focused on expanding its market presence in the pharmaceutical sector, particularly in the treatment of various infections and allergic conditions[124]. - The company aims to enhance its product portfolio through research and development of new drugs targeting specific health issues[124]. - The company is exploring partnerships with international firms to enhance its research capabilities and market reach[116]. Operational Challenges - The company reported a significant impact on operations due to the COVID-19 pandemic, affecting production and sales activities[6]. - The company faces risks related to the consistency evaluation of its generic drugs, which could affect market competitiveness if not completed on time[8]. - The company has seen an increase in accounts receivable, raising concerns about potential bad debts, and is implementing measures to strengthen management in this area[12]. - The company’s main raw materials are subject to price fluctuations due to external factors, which could impact production costs[12]. - The company’s ability to continue legal production of drugs is contingent on timely renewal of necessary regulatory certifications[13]. - The company acknowledges the potential for adverse changes in market conditions that could affect the expected economic benefits of its investment projects[13]. - The company emphasizes the importance of safety and environmental compliance in production processes[180]. Product Development and Portfolio - The company’s main business includes the research, production, and sales of pharmaceutical products, with a diverse product range including anti-infection drugs and cardiovascular medications[41]. - The leading products include Loxoprofen Sodium Gel and Levosetirizine Hydrochloride, which hold significant market shares in their respective categories[41]. - The company has developed 53 pharmaceutical excipients, ensuring high-quality production and a cost advantage in its formulation products[60]. - The company has 107 registered formulations, with 48 varieties and 61 product specifications included in the latest National Medical Insurance Directory[110]. - The consistency evaluation for the drug "Levocetirizine Hydrochloride Tablets" was approved in March 2019, indicating progress in the company's product development[110]. - The company has received approval for 107 formulation varieties and 19 raw material drug varieties, with 12 raw material drug varieties registered, indicating a comprehensive product structure[58]. - The company has registered 53 new trademarks, increasing its brand presence in the market[68]. - The company has expanded its product offerings with new packaging for various medications, including capsules and oral solutions, as of September 17, 2019[16]. Strategic Initiatives - The company plans to distribute a cash dividend of 0.36 yuan per 10 shares, based on a total of 234,680,000 shares[13]. - The company plans to acquire competitive products with good market prospects to enhance its product portfolio[52]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's product portfolio and increase revenue by 5% annually[80]. - The company aims to achieve steady growth in performance in 2020, focusing on enhancing R&D, production, and daily management[175]. - The company plans to prioritize the development of improved new drugs and external preparations, with a focus on a few selected generic drugs[176]. - The company will enhance its financial management system, focusing on comprehensive budgeting and cost control[180]. - The company plans to strengthen its marketing strategies by closely monitoring national policies and market trends[177]. - The company aims to improve its core competitiveness through resource integration and innovation in R&D and marketing[174]. - The company will focus on expanding its domestic market while further exploring international markets[174]. Shareholder Information - The cash dividend for the reporting period is set at RMB 0.36 per 10 shares, with a total cash dividend amounting to RMB 8,448,480[186]. - The total distributable profit for the year is RMB 55,065,853.69, with the cash dividend representing 100% of the total profit distribution[186]. - The company has maintained a consistent cash dividend policy over the past three years, with dividends distributed in 2017, 2018, and 2019[189]. - The company’s financial performance indicates a trend of decreasing profits over the past three years, with a notable drop from RMB 14,080,800 in 2017 to RMB 8,448,480 in 2019[189]. - The company has fulfilled its commitments related to shareholding and stock lock-up periods as stipulated during its initial public offering[190]. - The company’s actual controller and shareholders have committed to not transferring their shares for a period of 36 months from the date of listing[190]. - The company’s stock lock-up period will automatically extend by 6 months if the stock price falls below the initial public offering price for 20 consecutive trading days[193].

湖南九典制药股份有限公司 2019 年第三季度报告全文 湖南九典制药股份有限公司 2019 年第三季度报告 2019-073 2019 年 10 月 1 湖南九典制药股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人朱志宏、主管会计工作负责人熊英及会计机构负责人(会计主管 人员)王果声明：保证季度报告中财务报表的真实、准确、完整。 2 湖南九典制药股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|----------------|--------- ...

Financial Performance - The company reported a total revenue of 300 million RMB for the first half of 2019, representing a year-on-year increase of 15%[18]. - Net profit attributable to shareholders reached 50 million RMB, up 20% compared to the same period last year[18]. - Total revenue for the reporting period was ¥426,137,951.80, an increase of 18.19% compared to the same period last year[27]. - Net profit attributable to shareholders was ¥28,520,688.81, reflecting a growth of 2.17% year-over-year[27]. - The company achieved operating revenue of 426.14 million yuan, an increase of 18.19% compared to the same period last year[82]. - The net profit attributable to shareholders was 28.52 million yuan, reflecting a growth of 2.17% year-on-year[82]. Research and Development - The company has allocated 10 million RMB for R&D in new technologies, focusing on improving drug efficacy and safety[18]. - R&D investment accounted for 10.87% of the company's revenue during the reporting period, up from 7.17% in the previous year[60]. - The company focuses on independent research and development, complemented by collaborative development and technology introduction, to optimize existing products and meet market demands[46]. - The company holds 18 invention patents and has undertaken multiple national-level projects, including significant new drug creation projects[61]. - The company has completed the consistency evaluation for one generic drug and finished the process validation for five raw material drug varieties during the reporting period[82]. - Research and development investment increased by 145.08% to RMB 46,324,122.66 from RMB 18,901,440.84 year-on-year, indicating a significant focus on R&D projects[91]. Market Expansion and Strategy - The company plans to expand its product line by introducing three new drugs by the end of 2019, targeting a market share increase of 10% in the next fiscal year[18]. - Market expansion efforts include entering two new provinces, aiming for a 5% increase in regional sales by the end of the year[18]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the pharmaceutical industry[18]. - The company emphasizes the importance of managing distributors and promoting product brands to enhance sales scale and market coverage[45]. - The company has established a comprehensive marketing network with independent accounting for its clinical, raw materials, OTC, and international expansion divisions, enhancing its competitive advantage in drug procurement processes across various provinces[66]. - The company is actively expanding its market presence and enhancing brand image through increased media promotion[82]. Financial Management and Investments - The company will not distribute cash dividends for this fiscal year, opting to reinvest profits into business development[18]. - The total amount of funds raised during the reporting period was RMB 2,123.94 million[103]. - The cumulative amount of funds raised reached RMB 24,554.2 million, with no changes in usage[103]. - As of June 30, 2019, the company had utilized RMB 245,541,922.08 of the raised funds, with RMB 78,454,147.46 for project replacement and RMB 167,087,774.62 directly for investment projects[107]. - The company has not made any changes to the use of raised funds during the reporting period[108]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[111][112][113]. Risk Management - Risks identified include regulatory changes and market competition, with strategies in place to mitigate these challenges[18]. - The company faces significant risks from the evolving pharmaceutical industry policies, which could adversely affect its operations if not effectively managed[119]. - The company acknowledges the risks associated with drug development and consistency evaluation, committing to a comprehensive R&D system to minimize potential failures[120]. - Fluctuations in raw material prices pose a risk, but the company aims to diversify its material sources and manage procurement costs effectively[120]. - The company must maintain its production licenses and certifications to avoid operational disruptions, implementing strict internal management to ensure compliance[123]. - There are uncertainties regarding the effectiveness of fundraising projects, and the company is focused on internal management to ensure project success and mitigate financial impacts[124]. Corporate Governance and Compliance - The management team is stable and well-structured, focusing on performance evaluation and employee loyalty to ensure sustainable development[68]. - The company has not undergone any major litigation or arbitration matters during the reporting period[142]. - There are no significant related party transactions during the reporting period[146]. - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[145]. - The company has not experienced any penalties or rectification situations during the reporting period[144]. - The company has not reported any media controversies during the reporting period[143]. Environmental and Social Responsibility - The company has established an environmental monitoring plan and has commissioned a qualified unit for regular pollutant discharge testing[167]. - The wastewater treatment station has passed environmental acceptance and is operating normally, with no instances of exceeding discharge standards reported[166]. - The company plans to support 5-10 outstanding students from impoverished backgrounds with an annual grant of 5,000 yuan each, totaling 25,000 to 50,000 yuan for the year[167]. - The company has not implemented its annual precision poverty alleviation plan during the reporting period[170]. - The company will continue to focus on its core business while contributing to social welfare through its poverty alleviation initiatives[172]. Shareholder Information - The total number of shares before the change was 234,680,000, with 60.00% being restricted shares and 40.00% being unrestricted shares[179]. - The number of restricted shares decreased by 1,243,884, resulting in 139,567,188 restricted shares after the change, which is 59.47% of the total[179]. - The largest shareholder, Zhu Zhihong, holds 37.16% of the shares, totaling 87,210,000 restricted shares[183]. - The company has a total of 21,983 shareholders at the end of the reporting period[183]. - The controlling shareholder and actual controller of the company did not change during the reporting period[191]. - There were no changes in the shareholding of directors, supervisors, and senior management during the reporting period[199].

Financial Performance - Total revenue for Q1 2019 was CNY 178,432,234.08, representing a 5.82% increase compared to CNY 168,621,323.35 in the same period last year[9] - Net profit attributable to shareholders decreased by 18.58% to CNY 10,416,498.69 from CNY 12,793,394.77 year-on-year[9] - Net profit after deducting non-recurring gains and losses fell by 28.73% to CNY 8,972,799.71 compared to CNY 12,589,341.19 in the previous year[9] - Basic and diluted earnings per share decreased by 33.33% to CNY 0.04 from CNY 0.06 in the same period last year[9] - The company achieved operating revenue of 178.43 million yuan, a year-on-year increase of 5.82%[29] - The net profit attributable to shareholders was 10.42 million yuan, a year-on-year decrease of 18.58%[29] - Operating profit decreased to ¥10,950,802.98, down 29.3% from ¥15,491,396.35 in the previous period[79] - Net profit for the current period was ¥10,416,498.69, a decline of 18.5% compared to ¥12,793,394.77 in the previous period[79] Cash Flow and Assets - Operating cash flow improved by 21.48%, with a net cash flow from operating activities of CNY -20,630,363.28, up from CNY -28,635,250.43[9] - The cash flow from operating activities showed a net increase of 27.95% compared to the previous period, primarily due to increased cash receipts from sales[25] - Cash inflow from operating activities totaled 188,936,750.23, compared to 172,655,935.49 in the prior period, reflecting a growth of approximately 9.5%[94] - Net cash outflow from operating activities was -20,630,363.28, an improvement from -28,635,250.43 in the previous period[94] - The total current assets as of March 31, 2019, amount to 392,087,074.70 CNY, down from 465,914,718.28 CNY in December 2018[59] - The total assets at the end of the reporting period were CNY 905,216,159.84, down 4.03% from CNY 943,211,123.69 at the end of the previous year[9] - The total liabilities decreased from 225,051,689.91 to 176,640,227.37, a reduction of approximately 21.5%[62] - The total owner's equity increased from 718,159,433.78 to 728,575,932.47, reflecting a growth of about 1.9%[65] Expenses and Investments - Management expenses increased by 38.09% due to rising personnel reserve costs and depreciation[29] - R&D expenses rose by 87.15% as the company increased investment in new products and technologies[29] - Total operating costs increased to ¥169,135,024.68, up 10.2% from ¥153,496,687.42 in the previous period[76] - Research and development expenses rose significantly to ¥14,869,722.43, an increase of 87.5% from ¥7,945,214.91 in the previous period[76] - Cash outflow for investing activities was 57,326,964.15, up from 37,850,888.76 in the prior period[97] - The company has pre-invested 7,845.41 million CNY in fundraising projects before the funds were in place[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,019[12] - The largest shareholder, Zhu Zhihong, holds 37.16% of the shares, totaling 87,210,000 shares[12] Future Outlook and Strategy - The company is confident in future development with new products expected to be gradually launched[29] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[76] - The company is actively developing new products with market potential and high profit margins to mitigate the impact of price adjustments on profitability due to intensified competition in the pharmaceutical market[33] - The company intends to expand its market presence and maintain competitive advantages through increased R&D efforts and market promotion[37] Quality and Compliance - The company has established a strict quality management system to control the production process and mitigate risks related to external environmental changes affecting drug quality[36] - The company is focused on maintaining its production licenses and certifications to ensure uninterrupted operations in compliance with regulatory requirements[39] Risks and Challenges - The company recognizes the risks associated with the uncertainty of project completion and market conditions affecting the expected economic benefits of its investment projects[40] - The company is committed to enhancing its internal management to ensure timely completion of projects and to prepare for market expansion post-investment[40] Other Financial Information - The company received government subsidies amounting to CNY 1,715,815.08 during the reporting period[9] - The company reported a net interest income of 164.23 million CNY from raised funds after deducting bank fees[50] - The company paid 27,357,134.85 in taxes, compared to 18,332,020.28 in the prior period, indicating an increase in tax obligations[94] - The first quarter report was not audited[104] - The company has not applied the new financial instruments, revenue, and leasing standards adjustments for the current year[104]